Roquefort Investments PLC (GB:ROQ)
LSE:ROQ
Top Page
Roquefort Investments PLC
(LSE:ROQ)
Select Model
Select Model
Rating:44Neutral
Price Target:
1.50 p
▲(25.00% Upside)
Action:N/ADate:01/04/26
The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.
Roquefort Investments PLC (ROQ) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.68M
Dividend YieldN/A
Average Volume (3M)2.61M
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding163,726,290
10 Day Avg. Volume1,674,162
30 Day Avg. Volume2,613,232
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Roquefort Investments PLC Business Overview & Revenue Model
Company Description
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer....
How the Company Makes Money
null...
Roquefort Investments PLC Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 200.00K | 0.00 | 719.00 |
| Gross Profit | -2.70K | -16.00K | 200.00K | 0.00 | -9.35K |
| EBITDA | -926.73K | -1.11M | -1.93M | 0.00 | -352.40K |
| Net Income | -882.45K | -971.80K | -1.74M | -1.62M | -917.43K |
Balance Sheet | |||||
| Total Assets | 5.66M | 5.75M | 6.09M | 7.77M | 4.56M |
| Cash, Cash Equivalents and Short-Term Investments | 182.92K | 337.11K | 537.32K | 2.32M | 899.72K |
| Total Debt | 383.65K | 400.09K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 909.12K | 861.73K | 589.02K | 561.58K | 477.43K |
| Stockholders Equity | 4.75M | 4.89M | 5.50M | 7.21M | 4.08M |
Cash Flow | |||||
| Free Cash Flow | -645.62K | -783.73K | -1.79M | -1.58M | -2.62M |
| Operating Cash Flow | -588.75K | -783.73K | -1.73M | -1.58M | -2.62M |
| Investing Cash Flow | -57.06K | 0.00 | -52.57K | -103.48K | -1.11M |
| Financing Cash Flow | 236.00K | 584.91K | -58.00 | 3.10M | 4.63M |
Roquefort Investments PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £277.10M | -2.25 | 12.82% | ― | 1231.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £1.68M | -0.94 | -18.71% | ― | ― | ― | |
44 Neutral | £21.40M | -3.13 | -202.14% | ― | ― | 23.76% | |
44 Neutral | £15.00M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
43 Neutral | £9.91M | -4,173.96 | -433.59% | ― | ― | ― | |
42 Neutral | £290.87M | -1.74 | -361.23% | ― | ― | ― |
* Healthcare Sector Average
GB:ROQ
Roquefort Investments PLC
1.03
-0.88
-46.05%
GB:AVCT
Avacta Group plc
66.50
28.75
76.16%
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.50
0.85
51.52%
GB:PRTC
PureTech Health
114.00
-13.60
-10.66%
GB:SAR
Sareum Holdings
15.50
4.25
37.78%
GB:FAB
Fusion Antibodies Plc
12.00
5.45
83.21%
Roquefort Investments PLC Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Roquefort Therapeutics to buy AO-252 licence, raise £8.5m and move to AIM
Positive
Mar 2, 2026
Roquefort Therapeutics has agreed to acquire the exclusive worldwide licence to AO-252, a clinical-stage, orally administered, brain-penetrant small molecule inhibitor of TACC3 from Coiled Therapeutics Inc. The deal, valued at £31.875 million...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Roquefort Therapeutics to Acquire Cancer Drug AO-252 and Shift Listing to AIM
Positive
Feb 25, 2026
Roquefort Therapeutics plans to acquire worldwide exclusive rights to AO-252, a TACC3-targeting oncology drug candidate from Coiled Therapeutics and A2A Pharmaceuticals, while completing an associated equity fundraise and preparing documentation f...
Business Operations and Strategy
Roquefort Therapeutics Flags New Broker Research on Coiled and A2A Deal
Positive
Jan 15, 2026
Roquefort Therapeutics has announced that its broker, SP Angel Corporate Finance, has published a new research note analysing the company’s proposed transaction with clinical-stage oncology firm Coiled Therapeutics and AI-driven drug discove...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.